Stayble Therapeutics AB
- Biotech or pharma, therapeutic R&D
Stayble is seeking a global partner for STA363 - A phase 2b-ready asset targeting pain caused by disc herniation. Positive phase 1b data is available with established safety and efficacy on the key biomarker.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}